KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Share-based Compensation (2018 - 2025)

Castle Biosciences' Share-based Compensation history spans 7 years, with the latest figure at $11.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation changed 0.29% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $45.9 million, down 8.8%, while the annual FY2025 figure was $45.9 million, 8.8% down from the prior year.
  • Share-based Compensation for Q4 2025 was $11.4 million at Castle Biosciences, down from $12.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.5 million in Q1 2023 and bottomed at $4.8 million in Q2 2021.
  • The 5-year median for Share-based Compensation is $11.3 million (2025), against an average of $10.3 million.
  • The largest annual shift saw Share-based Compensation surged 211.54% in 2021 before it dropped 14.96% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $6.9 million in 2021, then surged by 44.84% to $9.9 million in 2022, then rose by 18.94% to $11.8 million in 2023, then decreased by 3.08% to $11.4 million in 2024, then decreased by 0.29% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Share-based Compensation are $11.4 million (Q4 2025), $12.1 million (Q3 2025), and $11.2 million (Q2 2025).